Abstract
Background: Baricitinib, commonly used for autoimmune diseases, is typically administered orally, which can lead to systemic adverse effects. A topical formulation could potentially offer localized therapeutic effects while minimizing these side effects. Objectives: This study focuses on developing a lipid-based topical formulation of baricitinib (BCT-OS) for treating psoriasis. Methods: The optimized formulation was then assessed for physical, chemical, and biopharmaceutical characterization. Furthermore, the anti-inflammatory efficacy of the formulation was tested in a model of psoriasis induced by imiquimod in mice, and its tolerance was determined by the evaluation of biomechanical skin properties and an inflammation test model induced by xylol in mice. Results: BCT-OS presented appropriate characteristics for skin administration in terms of pH, rheology, extensibility, and stability. The formulation also demonstrated a notable reduction in skin inflammation in the mouse model, and high tolerability without affecting the skin integrity. Conclusions: BCT-OS shows promise as an alternative treatment for psoriasis, offering localized therapeutic benefits with a potentially improved safety profile compared to systemic administration.
Share and Cite
MDPI and ACS Style
Mohammadi-Meyabadi, R.; Mallandrich, M.; Beirampour, N.; Garrós, N.; Espinoza, L.C.; Sosa, L.; Suñer-Carbó, J.; Rodríguez-Lagunas, M.J.; Garduño-Ramírez, M.L.; Calpena-Campmany, A.C.
Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis. Pharmaceutics 2024, 16, 1287.
https://doi.org/10.3390/pharmaceutics16101287
AMA Style
Mohammadi-Meyabadi R, Mallandrich M, Beirampour N, Garrós N, Espinoza LC, Sosa L, Suñer-Carbó J, Rodríguez-Lagunas MJ, Garduño-Ramírez ML, Calpena-Campmany AC.
Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis. Pharmaceutics. 2024; 16(10):1287.
https://doi.org/10.3390/pharmaceutics16101287
Chicago/Turabian Style
Mohammadi-Meyabadi, Roya, Mireia Mallandrich, Negar Beirampour, Núria Garrós, Lupe Carolina Espinoza, Lilian Sosa, Joaquim Suñer-Carbó, María José Rodríguez-Lagunas, María Luisa Garduño-Ramírez, and Ana C. Calpena-Campmany.
2024. "Lipid-Based Formulation of Baricitinib for the Topical Treatment of Psoriasis" Pharmaceutics 16, no. 10: 1287.
https://doi.org/10.3390/pharmaceutics16101287
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details
here.
Article Metrics
Article Access Statistics
For more information on the journal statistics, click
here.
Multiple requests from the same IP address are counted as one view.
, 
